ロード中...
Potential benefit of bosentan therapy in borderline or less severe pulmonary hypertension secondary to idiopathic pulmonary fibrosis—an interim analysis of results from a prospective, single-center, randomized, parallel-group study
BACKGROUND: No drugs have been approved for the treatment of patients with pulmonary hypertension (PH) secondary to idiopathic pulmonary fibrosis (IPF), particularly those with idiopathic honeycomb lung. This study was conducted to investigate the long-term efficacy and safety of bosentan for PH bas...
保存先:
| 出版年: | BMC Pulm Med |
|---|---|
| 主要な著者: | , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
BioMed Central
2017
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5729252/ https://ncbi.nlm.nih.gov/pubmed/29237441 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12890-017-0523-2 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|